About Us
What we do
Since 2008, Langlands & Associates Consulting Inc. has been providing services in various aspects of the development of new medicines, including discovery pharmacology, non-clinical and clinical development, expanded access programs, drug safety, regulatory affairs, project review and strategic planning.
John Langlands, Ph.D., President
John received his Doctorate from the University of Strathclyde in Glasgow (UK). He has over 30 years of experience directed towards the development of new medicines and has been involved in preclinical and clinical translational medicine approaches to drug development, the integration of various aspects of the drug development life cycle, and early access programs (EAP) bringing therapies to patients with difficult-to-treat conditions and limited treatment options.
John has held senior management positions in preclinical and clinical research at Inflazyme Pharmaceuticals, and was the Program Director for Pharmaceutical Medicine & Drug Development at UNSW in Sydney (AU).
He has also been serving as Head of Clinical Operations at DelMar Pharmaceuticals/Kintara Therapeutics, Chief Operating Officer at Rakovina Therapeutics Inc, and VP-Preclinical Research at Naegis Pharmaceuticals Inc. He is co-founder and advisor to MedaSystems Inc.
John is a member of Society for Neuro Oncology, European Society for Medical Oncology, and was a founding and past Chair of Vancouver Pharmaceutical and BioScience Society (PBSS).
Recent Presentations
Operationalize Early Access Programmes Europe (16-18 October 2023) London UK. Streamlining collaboration between sponsors and clinicians to improve an Early Access Program.
MedaSystems Webinar Series (12 December 2025). Lessons from the Field: A conversation on Expanded Access.